Response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600E MT colon cancer patients with acquired C-MET amplification and TPM4- ALK fusion: case report and review of literature
Shuai Zhang(Beijing Hospital), Yingying Huang(Nanfang Hospital), Xueqing Hu(Beijing Hospital), Zicheng Yu(Northeast Normal University), Yunbo Zhao(University of Science and Technology of China), Xiang‐Yang Wang(Harvard University), Zhongkang Li
Cited by 0
Related Papers
Holocene moisture evolution in arid central Asia and its out-of-phase relationship with Asian monsoon history
|Quaternary Science Reviews|2008|1.2k
Large stocks of peatland carbon and nitrogen are vulnerable to permafrost thaw
|Proceedings of the National Academy of Sciences|2020|796
The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients
|Biological Trace Element Research|1997|122
CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing
|Proceedings of the National Academy of Sciences|2023|92